EUVIMEDEUVIMED entdecken
Crossref

Identification of Patients with Early-Stage Hepatocellular Carcinoma Benefiting from Neoadjuvant Chemotherapy—A SEER-Based Study

Shigang Xu, Liwei Duan, William C Cho, Shuai Jin, Linhao Ma

Journal of Gastrointestinal Cancer · 2025-12 · 56 (1)

DOI: 10.1007/s12029-025-01264-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastrointestinal Cancer, online erschienen am 29.06.2025. Verfasst von Shigang Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency, the Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, 200434, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The effectiveness of neoadjuvant chemotherapy (NAC) for individuals with early-stage hepatocellular carcinoma (HCC) is still a subject of controversy and uncertainty. This study sought to create a risk categorization model using a nomogram to pinpoint patients with early-stage HCC that might derive benefits from NAC. METHODS: This retrospective cohort study was based on data from the SEER Research Plus database (April 2021 release), covering the years 2006 to 2018. The definition of NAC was chemotherapy performed prior to surgery, while that of no NAC (No-NAC) was surgery without chemotherapy before the operation. We implemented stepwise Cox regression to discover prognostic factors and utilized these factors to develop a nomogram for forecasting the 3-, 5-, and 10-year cancer-specific survival (CSS) for patients with early-stage HCC. We utilized receiver operating characteristic curves, calibration curves, and decision curve analysis to evaluate the prognostic capacity of the nomogram. Finally, prognostic stratification was performed based on the optimal boundary value of the nomogram score, and we utilized the Kaplan-Meier method to analyze the survival rate. RESULTS: A sum of 11,721 HCC patients was incorporated in the analysis. After adjustment through propensity score matching, the baseline characteristics of the NAC and No-NAC groups were not statistically different. A total of 4030 patients, with the clinical data of their marital status, tumor number, fibrosis, alpha fetoprotein, grade, age, T stage, tumor size, race, and surgical approach (i.e., 11 variables) were employed in the building of the nomogram. The constructed nomogram exhibited good discriminatory ability and accuracy in predicting CSS in patients with early-stage HCC. Based on the nomogram, individuals can be classified into three distinct risk categories. In the group identified as high-risk, the CSS of the patients was significantly enhanced by NAC. CONCLUSIONS: This study developed and validated a nomogram for predicting 3-, 5-, and 10-year CSS in early-stage HCC patients, incorporating demographic and clinical factors. Risk stratification identified high-risk patients who benefited significantly from NAC. These findings support personalized treatment decisions, though external validation is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsNeoadjuvant TherapyHumansFemaleMaleRetrospective StudiesSEER ProgramMiddle AgedNomogramsNeoplasm StagingPrognosisAgedChemotherapy, AdjuvantSurvival RateRisk Assessment

Stichwörter der Autor:innen

Cancer-specific survivalEarly-stage hepatocellular carcinomaNeoadjuvant chemotherapyNomogramRisk stratification

Autor:innen und Institutionen

  • Department of Emergency, the Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, 200434, China.
  • Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, SAR, China.
  • School of Biology and Engineering (School of Health and Medicine Modern Industry), Guizhou Medical University, Guiyang, China. jssss@gmc.edu.cn.
  • Department of Emergency, the Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, 200434, China. macro118@139.com.

Zitieren

APA

Xu, S., Duan, L., Cho, W. C., Jin, S., & Ma, L. (2025). Identification of Patients with Early-Stage Hepatocellular Carcinoma Benefiting from Neoadjuvant Chemotherapy—A SEER-Based Study. Journal of Gastrointestinal Cancer, 56(1). https://doi.org/10.1007/s12029-025-01264-2

Vancouver

Xu S, Duan L, Cho WC, Jin S, Ma L. Identification of Patients with Early-Stage Hepatocellular Carcinoma Benefiting from Neoadjuvant Chemotherapy—A SEER-Based Study. Journal of Gastrointestinal Cancer. 2025;56(1). doi:10.1007/s12029-025-01264-2

BibTeX
@article{Xu2025,
  author = {Xu, Shigang and Duan, Liwei and Cho, William C and Jin, Shuai and Ma, Linhao},
  title = {Identification of Patients with Early-Stage Hepatocellular Carcinoma Benefiting from Neoadjuvant Chemotherapy—A SEER-Based Study},
  journal = {Journal of Gastrointestinal Cancer},
  year = {2025},
  volume = {56},
  number = {1},
  doi = {10.1007/s12029-025-01264-2}
}
Kostenlos starten →